Health Care·Pharmaceuticals·$547.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.28 | N/A | +3.56% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $1.28 | N/A | +3.56% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed satisfaction with the EPS results, highlighting ongoing efforts in innovation. However, they did not provide specific guidance for future quarters.
We are pleased with our EPS performance this quarter.
Our focus remains on innovation and operational efficiency.
Johnson & Johnson's earnings report shows a positive surprise in EPS, indicating better-than-expected profitability. However, the stock fell slightly by 0.55%, suggesting that investors may have been looking for more comprehensive guidance or revenue details. The lack of revenue data and future guidance could have contributed to the stock's downward movement.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
BROWN & BROWN INC
Jul 18, 2011